| Heart failure
Kerendia vs Epaned
Side-by-side clinical, coverage, and cost comparison for heart failure.Deep comparison between: Kerendia vs Epaned with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpaned has a higher rate of injection site reactions vs Kerendia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epaned but not Kerendia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kerendia
Epaned
At A Glance
Oral
Once daily
Mineralocorticoid receptor antagonist
Oral
Once or twice daily
ACE inhibitor
Indications
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
- Hypertensive disease
- Heart failure
- Ventricular Dysfunction, Left
Dosing
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Hypertensive disease Adults: 5 mg once daily orally, titrated up to 40 mg daily; pediatric patients >1 month: 0.08 mg/kg (up to 5 mg) once daily; renal impairment (GFR <=30 mL/min) or dialysis: initial dose 2.5 mg daily.
Heart failure 2.5 mg twice daily orally, titrated up to 20 mg twice daily as tolerated; usually given in combination with diuretics and digitalis.
Ventricular Dysfunction, Left 2.5 mg twice daily orally, titrated up to 10 mg twice daily as tolerated.
Contraindications
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Most common (>1%) Fatigue, orthostatic effects, asthenia, cough, rash; in heart failure patients: hypotension, dizziness.
Serious Angioedema, hypotension, hepatic failure, renal impairment, hyperkalemia, cardiac arrest, myocardial infarction, cerebrovascular accident, neutropenia, thrombocytopenia, bone marrow depression.
Postmarketing Pancreatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, eosinophilic pneumonitis, pulmonary infiltrates, gynecomastia.
Pharmacology
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
ACE inhibitor; enalapril is hydrolyzed to enalaprilat, which inhibits angiotensin-converting enzyme, suppressing the renin-angiotensin-aldosterone system and thereby reducing plasma angiotensin II, vasopressor activity, and aldosterone secretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
Epaned
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Epaned
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Epaned
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Epaned.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KerendiaView full Kerendia profile
EpanedView full Epaned profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.